Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of 12 systematic review(s)/meta-analysis(es). ^[1-12]
• Exacerbation Rates: Benralizumab significantly reduced exacerbation rates in patients with severe eosinophilic asthma (relative risk (RR) ~0.59) compared to placebo. However, it was less effective than dupilumab (RR ~0.32) and tezepelumab (RR ~0.63) but similar in efficacy to mepolizumab (RR ~0.53 to 0.59).
• Lung Function (Forced Expiratory Volume in 1 Second (FEV₁) Improvements): Benralizumab demonstrated modest improvements in pre-bronchodilator FEV₁ (~0.08 to 0.15 L), smaller compared to dupilumab (~230 mL) and tezepelumab, though differences were not statistically significant. Both tezepelumab and dupilumab had a high probability (1.00) of improving FEV₁ by ≥100 mL above placebo.
• Asthma Control and Quality of Life: Benralizumab improved Asthma Control Questionnaire (ACQ) and Asthma Quality of Life Questionnaire (AQLQ) scores, but these improvements did not meet the minimum clinically important difference (MCID). Mepolizumab showed the most ACQ improvement, but not significantly different from benralizumab or tezepelumab.
• Subgroup Differences (Eosinophil Levels): In patients with higher blood eosinophil levels (≥300 cells/μL), dupilumab showed a more pronounced reduction in exacerbation rates compared to benralizumab. For lower eosinophil levels (<150 cells/μL), there was no significant difference between dupilumab and benralizumab.
• Benralizumab: Generally well-tolerated, with no significant excess of serious adverse events compared to placebo. However, 2.1% of patients discontinued benralizumab due to adverse events, compared to 0.9% for placebo. Benralizumab showed a higher incidence of antidrug antibodies (8.35%) compared to other biologics.
• Infectious Adverse Events: Benralizumab was associated with a higher incidence of infections, including pharyngitis and bronchitis, compared to mepolizumab and reslizumab. It also showed trends toward higher infection rates, particularly in suboptimal responders with concomitant infections and sputum neutrophilia.
• Most studies focused on patients with severe eosinophilic asthma, and benralizumab was effective in reducing exacerbation rates in both eosinophilic and non-eosinophilic participants, with no significant reduction seen in non-eosinophilic participants with other anti-interleukin-5 (IL-5) treatments.